Form 4 for DGX Quest Diagnostics
Accepted 2026-02-17 00:00:00 ET · period of report 2026-02-13 · accession 0001022079-26-000009 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2026-02-17 | 2026-02-13 | DGX | Doherty Catherine T. | EVP, Regional Businesses | M - OptEx | $112.17 | +26.2K | 94.2K | +38% | +$2.93M |
| DM | 2026-02-17 | 2026-02-13 | DGX | Doherty Catherine T. | EVP, Regional Businesses | S - Sale+OE | $206.15 | -26.2K | 70.0K | -27% | -$5.39M |
| D | 2026-02-17 | 2026-02-13 | DGX | Doherty Catherine T. | EVP, Regional Businesses | M - OptEx | $112.17 | -26.2K | 0 | -100% | -$2.93M |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-02-13 | M | A | 26,165 | $112.17 | 94,233 | D | — | — | |
| 2 | Common | Common Stock | 2026-02-13 | S | D | 10,122 | $206.37 | 73,538 | D | — | — | (F3) This transaction was executed in multiple trades at prices ranging from $205.770 to $206.7489. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. |
| 3 | Common | Common Stock | 2026-02-13 | S | D | 10,573 | $205.21 | 83,660 | D | — | — | (F2) This transaction was executed in multiple trades at prices ranging from $204.745 to $205.740. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. |
| 4 | Common | Common Stock | 2026-02-13 | S | D | 351 | $209.10 | 68,068 | D | — | — | (F6) This transaction was executed in multiple trades at prices ranging from $208.970 to $209.355. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. |
| 5 | Common | Common Stock | 2026-02-13 | S | D | 1,619 | $208.21 | 68,419 | D | — | — | (F5) This transaction was executed in multiple trades at prices ranging from $207.810 to $208.600. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. |
| 6 | Common | Common Stock | 2026-02-13 | S | D | 3,500 | $207.08 | 70,038 | D | — | — | (F4) This transaction was executed in multiple trades at prices ranging from $206.770 to $207.675. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. |
| 7 | Derivative | Non-Qualifed Stock Option (right to buy) | 2026-02-13 | M | D | 26,165 | $112.17 | 0 | D | $112.17 · — to 2030-02-18 | 26,165 Common Stock | (F8) The options vested in three equal annual installments beginning on the first annual anniversary of the grant date. |